Related Experiment Video
Updated: Jul 5, 2025
A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
Published on: September 13, 2022
Aptamer-Based Recognition of Breast Tumor Cells: A New Era for Breast Cancer Diagnosis
Natassia Silva de Araújo1, Aline Dos Santos Moreira1, Rayane da Silva Abreu1
1Laboratório de Genômica Aplicada e Bioinovações, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro 21040-900, RJ, Brazil.
Abstract:
Breast cancer is one of the leading causes of death among women worldwide and can be classified into four major distinct molecular subtypes based on the expression of specific receptors. Despite significant advances, the lack of biomarkers for detailed diagnosis and prognosis remains a major challenge in the field of oncology. This study aimed to identify short single-stranded oligonucleotides known as aptamers to improve breast cancer diagnosis. The Cell-SELEX technique was used to select aptamers specific to the MDA-MB-231 tumor cell line. After selection, five aptamers demonstrated specific recognition for tumor breast cell lines and no binding to non-tumor breast cells. Validation of aptamer specificity revealed recognition of primary and metastatic tumors of all subtypes. In particular, AptaB4 and AptaB5 showed greater recognition of primary tumors and metastatic tissue, respectively. Finally, a computational biology approach was used to identify potential aptamer targets, which indicated that CSKP could interact with AptaB4. These results suggest that aptamers are promising in breast cancer diagnosis and treatment due to their specificity and selectivity.
Insights
Researchers developed aptamers, which are short DNA/RNA molecules, to specifically detect breast cancer cells. These aptamers show promise for improving breast cancer diagnosis and potentially treatment by targeting tumor cells with high accuracy.
Area of Science:
- Biotechnology
- Oncology
- Molecular Biology
Background:
- Breast cancer is a leading cause of death globally, with molecular subtypes complicating diagnosis and treatment.
- Current diagnostic and prognostic tools lack sufficient biomarkers, presenting a challenge in oncology.
- Aptamers, as potential diagnostic tools, offer specificity and selectivity for cancer detection.
Purpose of the Study:
- To identify and characterize aptamers for improved breast cancer diagnosis.
- To develop novel biomarkers for differentiating tumor from non-tumor breast cells.
- To explore aptamer-target interactions for therapeutic applications.
Main Methods:
- Cell-SELEX (Systematic Evolution of Ligands by Exponential Enrichment) was employed to select aptamers against the MDA-MB-231 breast cancer cell line.
- Selected aptamers were validated for their specific binding to various breast tumor cell lines and tissues.
- Computational biology approaches were utilized to predict potential aptamer targets.
Main Results:
- Five aptamers were identified with specific recognition for breast tumor cell lines, showing no binding to non-tumor cells.
- Validated aptamers recognized primary and metastatic tumors across all molecular subtypes.
- AptaB4 and AptaB5 demonstrated enhanced recognition of primary tumors and metastatic tissue, respectively.
- Computational analysis suggested CSKP as a potential target for AptaB4.
Conclusions:
- Aptamers exhibit significant potential as diagnostic tools for breast cancer, offering high specificity and selectivity.
- The identified aptamers, particularly AptaB4 and AptaB5, could enhance the accuracy of breast cancer diagnosis.
- Further research into aptamer-target interactions may pave the way for novel breast cancer treatment strategies.
